Did you mean velneperit of s 2019 of ベルネペリット?
Displaying drugs 4976 - 5000 of 10517 in total
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Description: … tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of …
SUVN-502
SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer’s and Schizophrenia, an unmet medical need.
Investigational
Matched Description: … active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of …
SRT-2104
SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular, and Diabetes Mellitus, Type 2.
Investigational
Matched Description: … SRT2104 has been investigated for the basic science and treatment of Sepsis, PSORIASIS, Atrophy, Muscular …
SGI-1776
SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.
Investigational
Matched Description: … SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and …
SRT-1720
SRT-1720 is an activator of NAD(+)-dependent histone deacetylase SIRT1.
Investigational
Matched Description: … SRT-1720 is an activator of NAD(+)-dependent histone deacetylase SIRT1.[A253147] …
SC 41930
Investigational
SRX-1177
Investigational
SB 11285
SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. ... L45123] SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of …
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of …
SPK-7001
Investigational
SEA-BCMA
Investigational
SD118
SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.
Investigational
SB-249553
SB-249553 is a vaccine that has MAGE-3 cancer antigen and the Adjuvant SBAS-2. It is also under by GlaxoSmithKline to treat melanoma and lung cancer.
Investigational
SR 121463
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion ... of anti-diuretic hormone (SIADH). ... SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 ( …
SB-743921
Investigational
SR 140333
SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.
Investigational
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway …
TAK-751S
TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
Matched Description: … TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia …
Squalane
Experimental
Vet approved
4SC-203
4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Matched Description: … 4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia. …
Sobrerol
Experimental
SB-269970
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]
Investigational
Matched Description: … agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of …
Sorbitan
Experimental
SOR-C13
SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Investigational
Matched Description: … SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 …
Displaying drugs 4976 - 5000 of 10517 in total